One of the most promising therapies for the treatment of KRAS mutant colorectal cancers is onvansertib, a selective adenosine triphosphate competitive inhibitor of serine/threonine polo-like-kinase 1 (PLK1). Here, KRAS is linked to colorectal cancer.